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Abstract 
The purpose of this Editorial is to summarise the key recommendations of the Lancet 
Commission on Dementia Prevention, Intervention, and Care, reporting on the best 
available evidence to date on what we can do to prevent and intervene for dementia. We 
briefly describe the new life-course model of dementia prevention incorporating nine 
modifiable risk factors and their potential effect in reducing individuals’ risk of dementia. 
We also summarise the recommendations of the report about which pharmacological, 
psychological and social interventions are effective and improve outcomes for people 
with dementia and their families. Recent developments highlight that there is good 
potential for the prevention of dementia. Progress in evidence-based approaches indicate 
the potential for dementia care to be of high-quality and widely accessible. Acting upon 
this knowledge now will reduce the global burden of dementia and improve the lives of 
people living with dementia and their families.  
 
 





            
 
Lancet Commission on Dementia: A Call for Action 3 
Dementia is a clinical syndrome characterised by a decline from a previously attained 
cognitive level affecting a person’s activities of daily living and social functioning. 
Alzheimer’s disease is the commonest cause of dementia, followed by vascular dementia, 
dementia with Lewy bodies and frontotemporal dementia. Globally there were 
approximately 47 million people living with dementia in 2015, a number expected to rise 
to 131 million by 2050 (Prince et al 2015) primarily driven by increased longevity. The 
World Health Organisation’s Global Action Plan identifies dementia as a global priority 
urging key stakeholders to put in place necessary policies and resources that would 
ensure priority ‘to action in dementia’ (WHO April 3, 2017). The Lancet Commission on 
Dementia Prevention, Intervention, and Care provides an evidence-driven report that can 
act as a vehicle for implementing specific interventions for the prevention and 
management of dementia (Livingston et al 2017). 
     The aim of the report was to consolidate the evidence base through the involvement of 
experts from a variety of disciplines and countries and add to it. The specific 
recommendations are about transforming the lives of people with dementia and their 
families through prevention, intervention and care. The full report can be accessed here: 
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31363-6/fulltext. For 
this editorial we summarise the key recommendations of the Commission into two main 
categories; those related to prevention and those related to intervention and care.  
Prevention of dementia recommendations  
     The number of people with dementia is increasing globally, especially in low and 
middle income countries (Prince et al 2015). Recent studies suggest that changes have 
been occurring, with decreases in the age specific incidence or prevalence in USA, UK, 
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Sweden, Netherlands, France and Canada, probably reflecting reduced exposure to risk 
factors or increased resilience to cognitive decline, but in others for example Japan and 
China this is not the case (Chan et al 2013, Okamura et al 2013). Identifying and 
modifying risk could translate to a huge benefit for societies, individuals and health care 
systems. Prevention is always preferable to cure but this is particularly important in view 
of the absence of disease modifying treatments of the underlying illness. Any delay in the 
onset of dementia will be associated with significant health gains for individuals and 
society.       
     The Lancet Commission extends our knowledge of dementia prevention by calculating 
and presenting a new model approach to modifiable risk factors (Livingston et al 2017). 
This model estimates the population attributable fraction (PAF), which is the proportional 
(percentage) reduction in new cases of dementia that would occur if specific risk factors 
were completely eliminated. The risk factors included in this model are those identified 
by the UK National Institute of Health and Care Excellence (NICE. 2015)  and the US 
National Institutes of Health (NIH) (Daviglus et al 2010)  guidelines, with those 
qualifying on ‘best quality evidence’ being added. What is new and important about this 
model is that it takes a life-course approach to dementia prevention, considering that risk 
factors and their contribution to risk of dementia differ across the life span, and 
additionally calculates the contribution of emerging risk factors that have not been 
considered before - hearing loss and social isolation. These nine risk factors were 
education (the effect of which is mostly in early-life), hearing loss, hypertension, and 
obesity (mid-life) and late-life factors specifically smoking, depression, physical 
inactivity, social isolation, and diabetes (see Table 1). 
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     This new model found that more than a third of dementia cases are potentially 
preventable with collectively all nine factors accounting for 35% of the population 
dementia risk. Although it is impossible to completely eliminate these risks, the evidence 
of incidence reductions to date of around 20% strongly suggests that preventive strategies 
have the potential to delay or prevent dementia. Figure 1 shows the Lancet Commission 
life-course model of the nine key modifiable risk factors to dementia, delineating each 
factor’s contribution. 
     We were surprised to find that hearing loss was the largest contributor. This was 
accounted for by the strength of the association with dementia, almost doubling the risk, 
and by how common hearing loss is. Overall, we found that the most promising 
intervention targets were increasing education in early life, increasing physical activity 
and social engagement, reducing smoking, treating hypertension, diabetes, and hearing 
impairment. These are unlikely to be harmful and would also benefit people in other 
ways.  
Lancet Commission on Dementia: A Call for Action 6 
 
Figure 1: Life-course model of contribution of modifiable risk factors to dementia 
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Recommendations for intervention and care for people with dementia and their 
families 
     Diagnosis is a prerequisite for accessing interventions, and therefore we view timely 
diagnosis as the vehicle to accessing timely care (for further information on early 
diagnosis see the full Lancet Commission report; Livingston et al 2017). The 
Commission emphasises that although the underlying illness is not curable, many of the 
symptoms of dementia are now manageable, therefore the course of dementia and its 
symptoms changes with good dementia care. In the section below we review 
interventions that are effective and improve outcomes for people with dementia and their 
families and should therefore be implemented now.    
     The report highlights that good dementia care is individualised, which means that 
people with dementia and their families need to have their medical, social, and supportive 
care needs assessed and re-assessed over time as they change. They should be tailored to 
individual’s cultural needs, preferences, and priorities. Cholinesterase inhibitors are in 
routine use for treating cognitive symptoms, and although they do not change the 
neuropathology of the disease, they have a small but clinically important effect on 
cognition and function at all Alzheimer’s disease severities (Birks 2006), and are also 
effective in dementia with Lewy Bodies (McKeith et al 2000). Optimal doses also benefit 
global change and activities of daily living (Birks 2006).  
     Family carers of people with dementia are at increased risk of experiencing 
depression, with approximately 40% being at increased risk of developing clinically 
significant symptoms of depression and anxiety (Mahoney et al 2005). Treating carers’ 
psychological distress and specifically depression is important for the individual and in 
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addition, the presence of carer distress predicts care breakdown, admission to home care 
(Gallagher et al 2011), and increases risk of elder abuse (Cooper et al 2010). There are 
effective interventions such as the STrAtegies for RelaTives (START) (Livingston et al 
2013) or the Resources for Enhancing Alzheimer’s Caregiver Health intervention 
(REACH) (Gitlin et al 2003), which reduce risk of depression for carers and should 
therefore be made available. People with dementia and their families also need 
opportunities to discuss their views on plans about the future, considering the loss of 
capacity associated with more severe dementia. Health care professionals should discuss 
these views at an early stage to maximise the involvement of people with dementia. 
     Neuropsychiatric symptoms in dementia are common, affecting nearly every 
individual at some point in the illness. They increase severity of dementia symptoms and 
distress experienced by family carers and often mean that care at home breaks down 
(Savva et al 2009). These symptoms can have many causes and often several cluster 
together therefore their careful assessment is important (Lyketsos et al 2001). The 
Commission published algorithms incorporating strategies for managing neuropsychiatric 
symptoms of dementia particularly agitation, low mood, and psychosis which is usually 
psychological, social, and environmental, with pharmacological management restricted to 
people who experience severe symptoms. An important contribution of the Commission 
is the provision of guidance for clinicians and professionals involved in the care of people 
with dementia, describing the key principles and approaches to assessment and 
management of each of these symptoms (Livingston et al 2017).    
The report highlighted that people with dementia are vulnerable to risks including self-
neglect, vulnerability (including to exploitation), managing money, driving, or using 
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weapons (Cooper et al 2008, Cooper and Livingston 2014). Risk assessment and 
management at all stages is essential, balancing severity of risk against the person’s right 
to autonomy. Given that dementia shortens life span, and a third of older people die with 
dementia, the Commission recommends that professionals working in end-of-life care 
consider whether a patient has dementia, as they might be unable to make decisions, or 
express their needs and wishes. Technological interventions have the potential to improve 
care, assisting people with dementia to live in safe and stimulating environments, but 
caution is needed so that these interventions are for specific benefit rather than to replace 
social contact.  
Conclusions. This editorial has reviewed the key messages of the Lancet Commission on 
Dementia, placing an emphasis on what we can do now to prevent and intervene for 
dementia. In summary, the Commission’s key findings show that a large proportion of 
dementia is preventable and ‘acting now’ will have a huge benefit for societies and 
individuals worldwide. An important life-course approach, accommodating exposure to 
specific risk factors across the life span is presented, and urges us to think that ‘it is never 
too early and never too late’ to prevent dementia. The report also addresses the significant 
developments in interventions that improve outcomes for people with dementia and their 
families which should be routinely offered. This means we have made significant 
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Table 1 Potentially modifiable risk factors for dementia  
 




Mid-life factors (age 45-65 years) 
 
2. Hearing loss 
3. Hypertension  
4. Obesity 
 
Late-life factors (age > 65 years) 
 
5. Smoking  
6. Depression 
7. Physical inactivity 
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